Related Experiment Videos
IL-12-assisted immunization against Listeria monocytogenes using replication-restricted VSV-based vectors
Sheri D Klas1, Christy L Lavine, Michael A Whitt
1Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Vaccine
|November 29, 2005
Summary
A novel vesicular stomatitis virus (VSVDeltaG-IL12F) vaccine delivery system enhances immune responses. This system, when combined with a listerial antigen, successfully elicits protective immunity against Listeria.
Area of Science:
- Immunology
- Virology
- Vaccine Development
Background:
- Interleukin-12 (IL-12) is crucial for Th1-biased immunity but faces challenges in vaccine applications due to instability, cost, and toxicity.
- Developing stable and effective delivery systems for immunomodulators like IL-12 is essential for advancing vaccine technology.
Purpose of the Study:
- To engineer a replication-restricted vesicular stomatitis virus (VSV) expressing an IL-12 fusion protein (VSVDeltaG-IL12F) for enhanced vaccine efficacy.
- To evaluate the immunogenicity and protective potential of VSVDeltaG-IL12F when co-administered with a poorly immunogenic listerial antigen preparation (LMAg) in a mouse model.
Main Methods:
- Reverse genetics was employed to create a recombinant replication-restricted VSV lacking the glycoprotein gene (VSVDeltaG-IL12F).
- Mice were immunized with LMAg in combination with VSVDeltaG-IL12F.
- Immune responses, including T cell and B cell-mediated immunity, and protection against Listeria challenge were assessed.
Main Results:
- VSVDeltaG-IL12F successfully expressed large quantities of the IL-12 fusion protein.
- Co-administration of VSVDeltaG-IL12F with LMAg elicited potent T cell- and B cell-mediated immune responses.
- The combined immunization strategy conferred significant protective immunity against Listeria infection in mice.
Conclusions:
- VSVDeltaG-IL12F represents a promising vaccine platform for delivering IL-12 and enhancing immune responses.
- This novel approach overcomes limitations associated with traditional IL-12 use, offering a stable and effective method for inducing protective immunity.